-
Je něco špatně v tomto záznamu ?
Sarcopenia: revised European consensus on definition and diagnosis
AJ. Cruz-Jentoft, G. Bahat, J. Bauer, Y. Boirie, O. Bruyère, T. Cederholm, C. Cooper, F. Landi, Y. Rolland, AA. Sayer, SM. Schneider, CC. Sieber, E. Topinkova, M. Vandewoude, M. Visser, M. Zamboni, Writing Group for the European Working Group on...
Jazyk angličtina Země Velká Británie
Typ dokumentu konsensus - konference, časopisecké články, práce podpořená grantem
Grantová podpora
MC_UP_A620_1015
Medical Research Council - United Kingdom
MC_U147585827
Medical Research Council - United Kingdom
MC_UU_12011/2
Medical Research Council - United Kingdom
MC_U147585819
Medical Research Council - United Kingdom
MC_UP_A620_1014
Medical Research Council - United Kingdom
G0601019
Medical Research Council - United Kingdom
G0400491
Medical Research Council - United Kingdom
MC_U147585824
Medical Research Council - United Kingdom
10/33/04
Department of Health - United Kingdom
MC_UU_12011/1
Medical Research Council - United Kingdom
NLK
Free Medical Journals
od 1972
Open Access Digital Library
od 1996-01-01
Medline Complete (EBSCOhost)
od 1996-01-01 do Před 1 rokem
PubMed
30312372
DOI
10.1093/ageing/afy169
Knihovny.cz E-zdroje
- MeSH
- biologické markery MeSH
- biomedicínský výzkum MeSH
- kosterní svaly diagnostické zobrazování patologie MeSH
- lidé MeSH
- sarkopenie diagnóza ekonomika terapie MeSH
- svalová síla MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- konsensus - konference MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Evropa MeSH
Background: in 2010, the European Working Group on Sarcopenia in Older People (EWGSOP) published a sarcopenia definition that aimed to foster advances in identifying and caring for people with sarcopenia. In early 2018, the Working Group met again (EWGSOP2) to update the original definition in order to reflect scientific and clinical evidence that has built over the last decade. This paper presents our updated findings. Objectives: to increase consistency of research design, clinical diagnoses and ultimately, care for people with sarcopenia. Recommendations: sarcopenia is a muscle disease (muscle failure) rooted in adverse muscle changes that accrue across a lifetime; sarcopenia is common among adults of older age but can also occur earlier in life. In this updated consensus paper on sarcopenia, EWGSOP2: (1) focuses on low muscle strength as a key characteristic of sarcopenia, uses detection of low muscle quantity and quality to confirm the sarcopenia diagnosis, and identifies poor physical performance as indicative of severe sarcopenia; (2) updates the clinical algorithm that can be used for sarcopenia case-finding, diagnosis and confirmation, and severity determination and (3) provides clear cut-off points for measurements of variables that identify and characterise sarcopenia. Conclusions: EWGSOP2's updated recommendations aim to increase awareness of sarcopenia and its risk. With these new recommendations, EWGSOP2 calls for healthcare professionals who treat patients at risk for sarcopenia to take actions that will promote early detection and treatment. We also encourage more research in the field of sarcopenia in order to prevent or delay adverse health outcomes that incur a heavy burden for patients and healthcare systems.
Department Geriatrics University of Antwerp Ziekenhuisnetwerk Antwerpen Antwerp Belgium
Department of Epidemiology University of Oxford OX UK
Department of Geriatrics Hospital and University of Toulouse Toulouse France
Department of Health Sciences Faculty of Science Vrije Universiteit Amsterdam
Department of Medicine Geriatric section University of Verona Verona Italy
Department of Public Health Epidemiology and Health Economics University of Liège Liège Belgium
Instituto di Medicina Interna e Geriatria Università Cattolica del Sacro Cuore Roma Italy
MRC Lifecourse Epidemiology Unit University of Southampton
Research Department Centre Hospitalier Universitaire de Clermont Ferrand Clermont Ferrand France
Servicio de Geriatría Hospital Universitario Ramón y Cajal Madrid Spain
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20006760
- 003
- CZ-PrNML
- 005
- 20200525092140.0
- 007
- ta
- 008
- 200511s2019 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1093/ageing/afy169 $2 doi
- 035 __
- $a (PubMed)30312372
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Cruz-Jentoft, Alfonso J $u Servicio de Geriatría, Hospital Universitario Ramón y Cajal (IRYCIS), Madrid, Spain.
- 245 10
- $a Sarcopenia: revised European consensus on definition and diagnosis / $c AJ. Cruz-Jentoft, G. Bahat, J. Bauer, Y. Boirie, O. Bruyère, T. Cederholm, C. Cooper, F. Landi, Y. Rolland, AA. Sayer, SM. Schneider, CC. Sieber, E. Topinkova, M. Vandewoude, M. Visser, M. Zamboni, Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2,
- 520 9_
- $a Background: in 2010, the European Working Group on Sarcopenia in Older People (EWGSOP) published a sarcopenia definition that aimed to foster advances in identifying and caring for people with sarcopenia. In early 2018, the Working Group met again (EWGSOP2) to update the original definition in order to reflect scientific and clinical evidence that has built over the last decade. This paper presents our updated findings. Objectives: to increase consistency of research design, clinical diagnoses and ultimately, care for people with sarcopenia. Recommendations: sarcopenia is a muscle disease (muscle failure) rooted in adverse muscle changes that accrue across a lifetime; sarcopenia is common among adults of older age but can also occur earlier in life. In this updated consensus paper on sarcopenia, EWGSOP2: (1) focuses on low muscle strength as a key characteristic of sarcopenia, uses detection of low muscle quantity and quality to confirm the sarcopenia diagnosis, and identifies poor physical performance as indicative of severe sarcopenia; (2) updates the clinical algorithm that can be used for sarcopenia case-finding, diagnosis and confirmation, and severity determination and (3) provides clear cut-off points for measurements of variables that identify and characterise sarcopenia. Conclusions: EWGSOP2's updated recommendations aim to increase awareness of sarcopenia and its risk. With these new recommendations, EWGSOP2 calls for healthcare professionals who treat patients at risk for sarcopenia to take actions that will promote early detection and treatment. We also encourage more research in the field of sarcopenia in order to prevent or delay adverse health outcomes that incur a heavy burden for patients and healthcare systems.
- 650 _2
- $a biologické markery $7 D015415
- 650 _2
- $a biomedicínský výzkum $7 D035843
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a svalová síla $7 D053580
- 650 _2
- $a kosterní svaly $x diagnostické zobrazování $x patologie $7 D018482
- 650 _2
- $a sarkopenie $x diagnóza $x ekonomika $x terapie $7 D055948
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a konsensus - konference $7 D016446
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Bahat, Gülistan $u Department of Internal Medicine, Division of Geriatrics, Istanbul Medical School, Istanbul University, Istanbul, Turkey.
- 700 1_
- $a Bauer, Jürgen $u Center for Geriatric Medicine, University Heidelberg, Agaplesion Bethanien Krankenhaus, Heidelberg, Germany.
- 700 1_
- $a Boirie, Yves $u Research Department, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.
- 700 1_
- $a Bruyère, Olivier $u Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium.
- 700 1_
- $a Cederholm, Tommy $u Department of Public Health and Caring Sciences, Clinical Nutrition and Metabolism, Uppsala University, Uppsala, and Theme Ageing, Karolinska University Hospital, Stockholm, Sweden.
- 700 1_
- $a Cooper, Cyrus $u MRC Lifecourse Epidemiology Unit, University of Southampton; Southampton, UK; and Department of Epidemiology, University of Oxford, OX, UK.
- 700 1_
- $a Landi, Francesco $u Instituto di Medicina Interna e Geriatria, Università Cattolica del Sacro Cuore, Roma, Italy.
- 700 1_
- $a Rolland, Yves $u Department of Geriatrics, Hospital and University of Toulouse, Toulouse, France.
- 700 1_
- $a Sayer, Avan Aihie $u NIHR Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust and Faculty of Medical Sciences, Newcastle University, Newcastle, UK.
- 700 1_
- $a Schneider, Stéphane M $u Department of Gastroenterology and Clinical Nutrition, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Nice, France.
- 700 1_
- $a Sieber, Cornel C $u Department of Internal Medicine-Geriatrics, Institute for Biomedicine and Ageing, Friedrich-Alexander-University, Erlangen-Nürnberg, Germany.
- 700 1_
- $a Topinkova, Eva $u Department of Geriatrics, First Faculty of Medicine, Charles University and General Faculty Hospital, Prague, Czech Republic.
- 700 1_
- $a Vandewoude, Maurits $u Department Geriatrics, University of Antwerp, Ziekenhuisnetwerk Antwerpen (ZNA), Antwerp, Belgium.
- 700 1_
- $a Visser, Marjolein $u Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam; and the Amsterdam Public Health Research Institute; Amsterdam, The Netherlands.
- 700 1_
- $a Zamboni, Mauro $u Department of Medicine, Geriatric section, University of Verona, Verona, Italy.
- 710 2_
- $a Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2
- 773 0_
- $w MED00000173 $t Age and ageing $x 1468-2834 $g Roč. 48, č. 1 (2019), s. 16-31
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30312372 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200511 $b ABA008
- 991 __
- $a 20200525092140 $b ABA008
- 999 __
- $a ok $b bmc $g 1525618 $s 1096816
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 48 $c 1 $d 16-31 $e 20190101 $i 1468-2834 $m Age and ageing $n Age Ageing $x MED00000173
- GRA __
- $a MC_UP_A620_1015 $p Medical Research Council $2 United Kingdom
- GRA __
- $a MC_U147585827 $p Medical Research Council $2 United Kingdom
- GRA __
- $a MC_UU_12011/2 $p Medical Research Council $2 United Kingdom
- GRA __
- $a MC_U147585819 $p Medical Research Council $2 United Kingdom
- GRA __
- $a MC_UP_A620_1014 $p Medical Research Council $2 United Kingdom
- GRA __
- $a G0601019 $p Medical Research Council $2 United Kingdom
- GRA __
- $a G0400491 $p Medical Research Council $2 United Kingdom
- GRA __
- $a MC_U147585824 $p Medical Research Council $2 United Kingdom
- GRA __
- $a 10/33/04 $p Department of Health $2 United Kingdom
- GRA __
- $a MC_UU_12011/1 $p Medical Research Council $2 United Kingdom
- LZP __
- $a Pubmed-20200511